Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Sakana AI has opened a Recursive Self-Improvement Lab to test whether AI systems can help redesign and optimize future AI ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...

Executive function describes a set of cognitive processes and mental skills that help an individual plan, monitor, and successfully execute their goals. The “executive functions,” as they’re known, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

CEO Jensen Huang reiterated what he has been saying out loud all this time, although this time his words were a little bit ...

SCAIL-1 identifies the key bottlenecks that hinder character animation towards production level: how to represent the pose and how to inject the pose. However, the reliance on intermediate pose ...

But achieving recursive improvement alone does not suggest an immediate change in how industrial production occurs, societies organize, or markets function. More intelligence can’t learn what a drug ...

Spread the love“`html Understanding how to create a neural network can be a game-changer in the fields of artificial intelligence and machine learning. As industries increasingly rely on data-driven ...